Brief: Aligos Therapeutics Announces First Subjects Dosed In Phase 2a HERALD Study Of ALG-055009 In MASH Subjects
03/04/2024 13:39
April 3 (Reuters) - Aligos Therapeutics Inc ALGS.O :
* ALIGOS THERAPEUTICS ANNOUNCES FIRST SUBJECTS DOSED IN THE
PHASE
2A HERALD STUDY OF ALG-055009 IN MASH SUBJECTS
* ALIGOS THERAPEUTICS INC - TOPLINE SAFETY AND EFFICACY DATA
FROM
THIS STUDY ARE EXPECTED IN Q4 2024
Source text for Eikon: ID:nGNXGFnd2
Further company coverage: ALGS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aligos Therapeutics
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
U.S. RESEARCH ROUNDUP-Ciena Corp, Docusign, Snowflake
Brief: Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China
Aligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aligos Therapeutics Q2 net loss narrows on licensing revenue